New
HealthMore in Health →
Summit Therapeutics Drops After Apparent Phase 3 Miss Revives the Market’s Biotech Patience Problem
Summit Therapeutics shares fell sharply after what was described as an apparent statistical miss in part of a Phase 3 trial for ivonescimab, highlighting how little tolerance investors currently have for clinical gray
Key Takeaways
- Summit Therapeutics shares fell nearly 20% after the close on May 1, 2026.
- The trigger was described as an apparent statistical miss in part of a Phase 3 trial for ivonescimab.
DE
DT Editorial AI··via endpoints.news